Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 31st Annual J.P. Morgan Healthcare Conference 2013
12 slides from Jazz Pharmaceuticals's conference presentation, Jan 11, 2013
Slide 1: 31st Annual J.P. Morgan Healthcare Conference 2013
EXHIBIT 99.1 Relevant portion of the slides presented by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 8, 2013: 31st Annual 2013 Chairman Jazz Passion YearsPharmaceuticals Bruce innovation and Cozadd J.P. CEOMorgan Excellence Healthcare Con
Slide 2: Forward-Looking Statements
expectations. Forward-Looking “Safe This expectations future inherently and competition Prialt®; consuming increasingly protect approval; opportunities Pharmaceuticals’ 2012. 2 Jazzuncertainties, presentation Harbor” Jazz clinical intellectual successfully and involve Pharmaceuticals orand challengi
Slide 3: Non-GAAP Financial Measures
3 Non-GAAP In effected read financial business results directly accounting items, presentation this Jazz in and presentation, from conjunction comparable by based measures the inventory Jazz Financial period represent toincome their onPharmaceuticals pharmaceuticalsthese are internally to with Jazz
Slide 4: Strong Revenue Growth, Increasingly Diversified
Other 5 1. now 2. been $500 Jazz Strong reported actual is Erwinaze Xyrem $272 2011 Psychiatry $200 $150 $300 $600 $550 Based Pro Revenue pharmaceuticals completed 2010 $350 $450 $650 results forma accounted total on / Expect $174 $400 Erwinase guidance estimate may revenues on Total $250 for Growth
Slide 5: Strong Track Record of Adjusted EPS Growth
Strong 1. has January share 2. non-cash 2009 $1.55 Adjusted 2012G 2011 $0 $3.50 $5.00 $(0.50) $(0.23) $0.83 GAAP $2.00 $3.00 $2.50 $4.00 Jazz Guidance $0.50 not pharmaceuticals $(0.05) to $3.52 $4.00 $5.50 $3.50 $4.50 Track Income finalized 2009 18, adjusted $1.00 expenses. Earnings 2018, $2.50 $5.0
Slide 6: Sustained Earnings Growth from Continuing Operations
Sustained GAAP (in 1. January adjusted 1Q12 2Q12 3Q12 $30 $25 $100 YTD Jazz GAAP millions; $31 $75 pharmaceuticals 2012 $52 Income 18, $34 net income Earnings $66 =2012, income unaudited) $0 $95M $196M $79 from $50 from and 3Q12 Growth can Continuing exclude continuing be 2Q12 found – Continuing the
Slide 7: Xyrem—Strong Growth, Expect to Meet Guidance
Xyrem—Strong 1. meet 1Q12 3Q12 $73 Volume Based $89 the 2Q12 4Q12G Growth $103 guidance on guidance 11(YOY%) Sales 10% range provided 11% Growth provided 13% 9%2012 by Expect on Jazz Xyrem November to Pharmaceuticals Meet NetPrior Sales 8, 2012. Guidance Guidance: plc Jazz onPharmaceuticals $110-115
Slide 8: Erwinaze/Erwinase Net Sales
Erwinaze/Erwinase asparaginase Erwinaze Erwinia 1. $50 2012, The Pharmaceuticals 2. 3. 1Q12 4Q12G $27-31 Jazz Pro Jazz Company pharmaceuticals 2Q12 the forma Pharmaceuticals 18 $332 Chrysantemi closing Expect 3Q12 net 2012 $332,3 currently sales has date to net –not Exceed $32 Aestimate sales ofNew
Slide 9: Reconciliation of GAAP Net Income to Adjusted Net Income
Reconciliation asset diluted (1) Jazz$125 pharmaceuticals amortization share 7 21(EPS) 11 of$165 GAAP Stock-based Adjusted $2.67 Net $3.52 Income netcompensation income/(loss) 47—1 and EPS 2010expense toper (1) Adjusted diluted $33Transaction 8 8—$61 Net shareIncome (EPS) $0.83 related and Shares $1
Slide 10: Reconciliation of 2012 Guidance
Reconciliation operations contingent per 1. financial Adjustments: Guidance diluted results Intangible consideration share provided offor amounts GAAP the asset byyear Income Other Jazz Adjusted amortization ended Pharmaceuticals non-cash from December netContinuing income Share-based expense 31, pl
Slide 11: Reconciliation of GAAP Income from Continuing Operations
Reconciliation asset consideration Jazz pharmaceuticals amortization Other of GAAP Share-based non-cash Income expense compensation from Income Continuing expense tax adjustments Operations Purchase to Adjusted accounting Adjustednet Netinventory income Income 3Q12 fair in 1Q12-3Q12 value $34 20step
Slide 12: Relevant Portion of Transcript of Oral Presentation
Relevant portion of the transcript of the oral presentation by Jazz Pharmaceuticals plc at the J.P. Morgan Healthcare Conference in San Francisco, California on January 8, 2013 accompanying the above slides: Bruce C. Cozadd, Chairman & CEO, Jazz Pharmaceuticals plc ... I will start by reminding you
Jazz Pharmaceuticals — 31st Annual J.P. Morgan Healthcare Conference 2013 on 6ix